[PDF][PDF] Targeted therapeutic options in early and metastatic NSCLC-overview
G Gálffy, É Morócz, R Korompay, R Hécz… - Pathology and …, 2024 - por-journal.com
In recent years, there has been an expansion in the treatment options of non-small cell lung
cancer (NSCLC) with the advent of targeted therapies and immuno-oncology therapies [1 …
cancer (NSCLC) with the advent of targeted therapies and immuno-oncology therapies [1 …
A Functional Genomics Review of Non-Small-Cell Lung Cancer in Never Smokers
M Hamouz, RY Hammouz, MA Bajwa… - International Journal of …, 2023 - mdpi.com
There is currently a dearth of information regarding lung cancer in never smokers (LCINS).
Additionally, there is a difference in somatic mutations, tumour mutational burden, and …
Additionally, there is a difference in somatic mutations, tumour mutational burden, and …
[HTML][HTML] Association between cigarette smoking history, metabolic phenotypes, and EGFR mutation status in patients with non-small cell lung cancer
X Zhang, X Guo, Q Gao, J Zhang, J Zheng… - Journal of Thoracic …, 2023 - ncbi.nlm.nih.gov
Background Cigarette smoking exerts a significant impact on metabolic phenotypes and
epidermal growth factor receptor (EGFR) mutation status; however, their correlation remains …
epidermal growth factor receptor (EGFR) mutation status; however, their correlation remains …
Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report
S Boukansa, I Mouhrach, F El Agy, S El Bardai… - Plos one, 2024 - journals.plos.org
Background Non-small cell lung cancer (NSCLC) remains a significant global health
concern, with EGFR mutations playing a pivotal role in guiding treatment decisions. This …
concern, with EGFR mutations playing a pivotal role in guiding treatment decisions. This …
Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I …
G Li, M Fang, Y Zhou, X Liu, P Tian, F Mei - Heliyon, 2023 - cell.com
Background Advanced non-small cell lung cancer (NSCLC) is often complicated by
leptomeningeal metastases (LMs), especially in patients carrying EGFR mutations. EGFR …
leptomeningeal metastases (LMs), especially in patients carrying EGFR mutations. EGFR …
[HTML][HTML] Clinical value of peripheral blood circulating tumor DNA in predicting the efficacy of immunotherapy for non-small cell lung cancer
J Wang, X Fan, J Zhang, C Huang - Journal of Thoracic Disease, 2023 - ncbi.nlm.nih.gov
Background The high expression of programmed cell death 1-ligand 1 (PD-L1) is a valid
biological indicator of the therapeutic benefit of pembrolizumab in non-small cell lung cancer …
biological indicator of the therapeutic benefit of pembrolizumab in non-small cell lung cancer …
[PDF][PDF] Prevalence, real-world treatment patterns and survival outcomes of uncommon EGFR mutations in non-small cell lung cancer (NSCLC) patients in Canada
L Esveld - 2023 - studenttheses.uu.nl
Methode Er is een retrospectieve, observationele cohortstudie uitgevoerd onder patiënten
met EGFR gemuteerde niet-kleincellig longkanker. Gegevens omtrent prevalentie, klninsch …
met EGFR gemuteerde niet-kleincellig longkanker. Gegevens omtrent prevalentie, klninsch …